203 related articles for article (PubMed ID: 34250945)
1. Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy.
van As D; Okkersen K; Bassez G; Schoser B; Lochmüller H; Glennon JC; Knoop H; van Engelen BGM; 't Hoen PAC;
J Neuromuscul Dis; 2021; 8(6):1031-1046. PubMed ID: 34250945
[TBL] [Abstract][Full Text] [Related]
2. Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial.
van Engelen B;
Trials; 2015 May; 16():224. PubMed ID: 26002596
[TBL] [Abstract][Full Text] [Related]
3. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.
Okkersen K; Jimenez-Moreno C; Wenninger S; Daidj F; Glennon J; Cumming S; Littleford R; Monckton DG; Lochmüller H; Catt M; Faber CG; Hapca A; Donnan PT; Gorman G; Bassez G; Schoser B; Knoop H; Treweek S; van Engelen BGM;
Lancet Neurol; 2018 Aug; 17(8):671-680. PubMed ID: 29934199
[TBL] [Abstract][Full Text] [Related]
4. How to capture activities of daily living in myotonic dystrophy type 2?
Montagnese F; Rastelli E; Stahl K; Massa R; Schoser B
Neuromuscul Disord; 2020 Oct; 30(10):796-806. PubMed ID: 32888768
[TBL] [Abstract][Full Text] [Related]
5. Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients.
Symonds T; Randall JA; Campbell P
Muscle Nerve; 2017 Jul; 56(1):86-92. PubMed ID: 27862031
[TBL] [Abstract][Full Text] [Related]
6. Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ).
Hermans MC; Faber CG; De Baets MH; de Die-Smulders CE; Merkies IS
Neuromuscul Disord; 2010 May; 20(5):310-8. PubMed ID: 20363134
[TBL] [Abstract][Full Text] [Related]
7. Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study.
Baldanzi S; Bevilacqua F; Lorio R; Volpi L; Simoncini C; Petrucci A; Cosottini M; Massimetti G; Tognoni G; Ricci G; Angelini C; Siciliano G
Orphanet J Rare Dis; 2016 Apr; 11():34. PubMed ID: 27044540
[TBL] [Abstract][Full Text] [Related]
8. Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1.
Wenninger S; Cumming SA; Gutschmidt K; Okkersen K; Jimenez-Moreno AC; Daidj F; Lochmüller H; Hogarth F; Knoop H; Bassez G; Monckton DG; van Engelen BGM; Schoser B
Neurol Genet; 2021 Apr; 7(2):e572. PubMed ID: 33884298
[TBL] [Abstract][Full Text] [Related]
9. Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA).
DiPaolo G; Jimenez-Moreno C; Nikolenko N; Atalaia A; Monckton DG; Guglieri M; Lochmüller H
J Neurol; 2017 Apr; 264(4):701-708. PubMed ID: 28168524
[TBL] [Abstract][Full Text] [Related]
10. Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood.
van Cruchten RTP; van As D; Glennon JC; van Engelen BGM; 't Hoen PAC; ;
BMC Med; 2022 Nov; 20(1):395. PubMed ID: 36352383
[TBL] [Abstract][Full Text] [Related]
11. Body composition and clinical outcome measures in patients with myotonic dystrophy type 1.
Sedehizadeh S; Brook JD; Maddison P
Neuromuscul Disord; 2017 Mar; 27(3):286-289. PubMed ID: 28082208
[TBL] [Abstract][Full Text] [Related]
12. Structural white matter networks in myotonic dystrophy type 1.
van Dorst M; Okkersen K; Kessels RPC; Meijer FJA; Monckton DG; van Engelen BGM; Tuladhar AM; Raaphorst J;
Neuroimage Clin; 2019; 21():101615. PubMed ID: 30522973
[TBL] [Abstract][Full Text] [Related]
13. Reliability of the Apathy Evaluation Scale in Myotonic Dystrophy Type 1.
Gallais B; Gagnon C; Côté I; Forgues G; Laberge L
J Neuromuscul Dis; 2018; 5(1):39-46. PubMed ID: 29278897
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and correlates of apathy in myotonic dystrophy type 1.
Gallais B; Montreuil M; Gargiulo M; Eymard B; Gagnon C; Laberge L
BMC Neurol; 2015 Aug; 15():148. PubMed ID: 26296336
[TBL] [Abstract][Full Text] [Related]
15. Disease burden of myotonic dystrophy type 1.
Landfeldt E; Nikolenko N; Jimenez-Moreno C; Cumming S; Monckton DG; Gorman G; Turner C; Lochmüller H
J Neurol; 2019 Apr; 266(4):998-1006. PubMed ID: 30788616
[TBL] [Abstract][Full Text] [Related]
16. The Myotonic Dystrophy Health Index: Italian validation of a disease-specific outcome measure.
Sansone VA; Lizio A; Greco L; Gragnano G; Zanolini A; Gualandris M; Iatomasi M; Heatwole C
Neuromuscul Disord; 2017 Nov; 27(11):1047-1053. PubMed ID: 28890289
[TBL] [Abstract][Full Text] [Related]
17. Participation and the Role of Neuropsychological Functioning in Myotonic Dystrophy Type 1.
Van Heugten C; Meuleman S; Hellebrekers D; Kruitwagen-van Reenen E; Visser-Meily J
J Neuromuscul Dis; 2018; 5(2):205-214. PubMed ID: 29865086
[TBL] [Abstract][Full Text] [Related]
18. Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.
Heatwole C; Bode R; Johnson N; Dekdebrun J; Dilek N; Heatwole M; Hilbert JE; Luebbe E; Martens W; Mcdermott MP; Rothrock N; Thornton C; Vickrey BG; Victorson D; Moxley R
Muscle Nerve; 2014 Jun; 49(6):906-14. PubMed ID: 24142420
[TBL] [Abstract][Full Text] [Related]
19. Urinary titin in myotonic dystrophy type 1.
Varga D; Perecz B; Fülöp K; Sipos A; Janszky JV; Hajdú N; Pál E
Muscle Nerve; 2023 Aug; 68(2):215-218. PubMed ID: 37291994
[TBL] [Abstract][Full Text] [Related]
20. Characterization of EEG-based functional brain networks in myotonic dystrophy type 1.
Biere J; Okkersen K; van Alfen N; Kessels RPC; Gouw AA; van Dorst M; van Engelen B; Stam CJ; Raaphorst J;
Clin Neurophysiol; 2020 Aug; 131(8):1886-1895. PubMed ID: 32590320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
